---
title: "ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) — 10-K Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292668539.md"
description: "AngioDynamics Inc reported FY2026 revenue of $320.17M, up 9.5% YoY, driven by Med Tech growth. However, the company posted a net loss of ($36.74M) and diluted EPS of ($0.88), widening from the prior year. Management is restructuring manufacturing to outsource production for $15M in annual savings. Product momentum was supported by Auryon, NanoKnife, and thrombus platform advancements, alongside improved commercial execution."
datetime: "2026-07-14T19:45:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292668539.md)
  - [en](https://longbridge.com/en/news/292668539.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292668539.md)
generator: "portal-rs"
---

# ANGIODYNAMICS INC FY 2026: Revenue $320.17M, EPS ($0.88) — 10-K Summary

AngioDynamics Inc reported fiscal 2026 revenue of $320.17M, up 9.5% from $292.5M a year earlier, while the company recorded a net loss of ($36.74M) and diluted loss per share of ($0.88) for the year — a slightly larger loss versus fiscal 2025. This summary is based on the company's Form 10-K for the year ended 2026.

**Financial Highlights**

Metric

Current year

Prior year

YoY change

Revenue¹

$320.17M

$292.5M

9.5%

Net income²

($36.74M)

($33.99M)

(8.1%)

Diluted EPS³

($0.88)

($0.83)

(6%)

*¹ Reported as “Net sales”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.*

**Business Highlights**

-   Revenue growth of 9.5% was driven by Med Tech (up 18.4%) with modest gains in Med Device.
-   Management is restructuring manufacturing to outsource most production while retaining select operations in Queensbury, targeting approximately $15M of annual savings.
-   Product momentum came from Auryon, NanoKnife and the thrombus platform, supported by new IDEs, FDA clearances and published clinical data.
-   Commercial execution improvements — including enhanced sales and physician training and targeted marketing — supported U.S. and international penetration.

Original SEC Filing: ANGIODYNAMICS INC \[ ANGO \] - 10-K - Jul. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ANGO.US](https://longbridge.com/en/quote/ANGO.US.md)

## Related News & Research

- [AngioDynamics, Inc. $ANGO Shares Purchased by Bank of America Corp DE](https://longbridge.com/en/news/297281311.md)
- [ANGO: Med Tech growth and margin expansion drove profitability and a strong, debt-free balance sheet](https://longbridge.com/en/news/292604430.md)
- [NAPC Defense announces availability of fiscal 2026 Form 10-K report](https://longbridge.com/en/news/296821941.md)
- [CXJ Group flags late filing of annual report for year ended May 31, 2026](https://longbridge.com/en/news/297305685.md)
- [REP: Shifted to healthcare focus, reduced gearing, and guided high-yield distributions for FY27](https://longbridge.com/en/news/296962558.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**